MX2021014166A - Composicion farmaceutica de compuesto de piridina amina y aplicacion de la misma en cancer de pulmon microcitico ros1 positivo. - Google Patents

Composicion farmaceutica de compuesto de piridina amina y aplicacion de la misma en cancer de pulmon microcitico ros1 positivo.

Info

Publication number
MX2021014166A
MX2021014166A MX2021014166A MX2021014166A MX2021014166A MX 2021014166 A MX2021014166 A MX 2021014166A MX 2021014166 A MX2021014166 A MX 2021014166A MX 2021014166 A MX2021014166 A MX 2021014166A MX 2021014166 A MX2021014166 A MX 2021014166A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
ros1
application
lung cancer
small cell
Prior art date
Application number
MX2021014166A
Other languages
English (en)
Inventor
Hao Zhou
Bo Jiang
Jie Chen
Ping Dong
Xiquan Zhang
Xifeng Lu
Lihui Dong
Xinlu Li
Xiongxiong He
Xiandong Zhao
Zekai Zhao
Hongyun Wang
Tie Yang
Jiaojiao Jia
Xunqiang Wang
Nan Su
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2021014166A publication Critical patent/MX2021014166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Una composición farmacéutica de compuesto de piridina amina y una aplicación de la misma en cáncer de pulmón no microcítico ROS1 positivo. Específicamente, una composición farmacéutica que comprende el compuesto de fórmula (I) o una sal farmacéuticamente aceptable, relleno, agente lubricante o agente disgregante del mismo, siendo el contenido de agua del relleno de = 2 % en peso. La composición farmacéutica tiene buena estabilidad y fluidez, y es adecuada para la producción industrial. Una aplicación del compuesto de fórmula (I) o la sal farmacéuticamente aceptable del mismo en fármacos para la prevención o el tratamiento del cáncer de pulmón no microcítico ROS1 positivo.
MX2021014166A 2019-05-22 2020-05-22 Composicion farmaceutica de compuesto de piridina amina y aplicacion de la misma en cancer de pulmon microcitico ros1 positivo. MX2021014166A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910427881 2019-05-22
CN201910427849 2019-05-22
PCT/CN2020/091827 WO2020233710A1 (zh) 2019-05-22 2020-05-22 吡啶胺化合物的药物组合物及其在ros1阳性非小细胞肺癌中的应用

Publications (1)

Publication Number Publication Date
MX2021014166A true MX2021014166A (es) 2022-01-04

Family

ID=73458374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014166A MX2021014166A (es) 2019-05-22 2020-05-22 Composicion farmaceutica de compuesto de piridina amina y aplicacion de la misma en cancer de pulmon microcitico ros1 positivo.

Country Status (4)

Country Link
CN (1) CN113747900B (es)
BR (1) BR112021023445A8 (es)
MX (1) MX2021014166A (es)
WO (1) WO2020233710A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022282A1 (zh) * 2022-07-25 2024-02-01 正大天晴药业集团股份有限公司 吡啶胺化合物在特定ros1基因融合的非小细胞肺癌中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850328B (zh) * 2011-07-01 2014-12-24 苏州东南药业股份有限公司 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途
JP2014526524A (ja) * 2011-09-21 2014-10-06 テリジーン リミテッド キナーゼ阻害剤としてのピリジン化合物
CN106349222B (zh) * 2012-04-22 2019-03-05 东南大学 克里唑替尼前药及其制备方法与用途
CN103263416A (zh) * 2013-04-28 2013-08-28 杭州鸿运华宁生物医药工程有限公司 一种吡啶胺化合物在制备适于口服给药的治疗肺癌的药物中的应用
CN104557869B (zh) * 2013-10-25 2017-09-26 正大天晴药业集团股份有限公司 一种吡啶胺化合物富马酸盐的晶型
CN104557870B (zh) * 2013-10-25 2017-12-08 正大天晴药业集团股份有限公司 一种吡啶胺化合物的富马酸盐
US20170000784A1 (en) * 2013-12-08 2017-01-05 Van Andel Research Institute Autophagy Inhibitors
AU2015392050B2 (en) * 2015-04-23 2020-01-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fumarate of pyridylamine compound and crystals thereof
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
CN108721243B (zh) * 2017-04-25 2022-07-08 正大天晴药业集团股份有限公司 克唑替尼药物组合物及其制备方法

Also Published As

Publication number Publication date
WO2020233710A1 (zh) 2020-11-26
CN113747900A (zh) 2021-12-03
BR112021023445A2 (pt) 2022-01-11
CN113747900B (zh) 2024-04-02
BR112021023445A8 (pt) 2023-10-10

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
TW200639156A (en) New compounds
TNSN07419A1 (en) Methods for treating drug resistant cancer
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
MX2019006843A (es) Inhibidor de cdk4/6.
MX2021014680A (es) Derivado de benzotriazol.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MY194711A (en) Novel annelated phenoxyacetamides
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
MX2021005944A (es) Inhibidores de rip1.
MX2021014166A (es) Composicion farmaceutica de compuesto de piridina amina y aplicacion de la misma en cancer de pulmon microcitico ros1 positivo.
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.